Canada: Pharma And Biologics Disputes In Canada—Big Changes For Big And Small Molecule Litigation

Last Updated: August 7 2017
Article by Dominique T. Hussey, L.E. Trent Horne and Jeilah Y. Chan

The patent litigation that propels generic and biosimilar products to market will soon change dramatically. July 15, 2017, marked the release of long-awaited proposed amendments to the Patented Medicines (Notice of Compliance) Regulations, which govern patent infringement and invalidity disputes involving patented medicines between "first" and "second" persons (i.e., brand v. generic and biologic v. biosimilar). The resolution of these disputes determines the timing of market approval of generic and biosimilar products. The proposed regulations are subject to a brief public consultation period until the end of July. The amendments could affect new cases starting as early as September 21, 2017, when the Comprehensive Economic Trade Agreement (CETA) that inspired the changes will likely take effect.

Legislative changes always bring new challenges and opportunity. In high-stakes pharmaceutical and biosimilar litigation, the parties involved rarely agree on the interpretation of the governing legislation—but it is beyond dispute that the proposed changes will profoundly affect their respective decisions on business, marketing, litigation and negotiation strategy.

IP Type



Assuming the proposed regulations are promulgated in their current form, some of the key differences between the old regulations and the new are the following:

Old: Applications 


New: Actions 

Litigation proceeded by application. Witnesses swore affidavits and were cross-examined before a court reporter. There was no documentary or oral discovery or live testimony. The case was argued at a hearing on a paper record.  

Litigation will proceed by action. There will be oral and documentary discovery, including certain mandatory productions by both parties, live witnesses and a trial.

Old: Double Jeopardy   New: Final Determinations of Patent Invalidity and Infringement
The decision that a patent was valid and infringed prevented the Minister of Health from granting market authorization to a generic or biosimilar drug submission. A decision to the contrary did not prevent approval, but also did not constitute a final determination of invalidity or infringement. As a result, after the generic launched its product, the application could be and often was followed by an infringement suit based on the very same subject matter, and at times with the opposite outcome.  

Determinations of invalidity and infringement will now be final as between the parties. Further, the First Person must take the opportunity to litigate, within the time limits established by the regulations, those patents it chooses to list on the Patent Register (to be governed by the regulation). Failure to do so may mean estoppel from suing on those patents in the future.

Old: 24-Month Stay on Market Approval or Bust

  New: First Person Can Waive 24-Month Stay; Generics and Biosimilars Launch at Risk

The 24-month stay on generic or biosimilar regulatory approval of the product at issue was triggered when the First Person started an application. The stay remained in place until patent issues were resolved between the parties or 24 months elapsed—whichever came first. Patent issues could be resolved (at least the first time) before the generic or biosimilar launched its product.


The First Person will now be able to waive the 24-month stay so the Minister of Health can grant market approval to the generic or biosimilar product while the patent proceedings continue.

Old: First Persons' Appeals Sometimes Moot 


New: Appeals Guaranteed 

Once the generic or biosimilar received market approval, for example, where 24 months had elapsed, or the generic or biosimilar had prevailed and the First Person awaited appeal, the First Person's patent proceedings were deemed moot. This meant that the First Person sometimes could not appeal an adverse decision


The First Person will now be guaranteed a right of appeal from an adverse decision.

Old: Compensatory Damages for Market Delay Within a Defined Period

  New: First Person Can Control Eligibility for Compensatory Damages

The generic or biosimilar was entitled to damages incurred during the period that the 24-month stay prevented sales of the product; those sales would have been made "but for" the effect of the regulations, ending on the day of approval.


The generic or biosimilar will still be entitled to damages for the "but-for" period and now beyond, but the First Person will be able to waive the 24-month period and avoid liability for damages. That First Person could now face generic or biosimilar competition immediately, but the new entrant will risk liability for damages for patent infringement.

Old: Detailed Statement Set Litigation Issues in Stone   New: Pleadings Govern Litigation
Generics and biosimilars were required to serve detailed statements of fact and law that confined their allegations of invalidity and infringement. The allegations could not be changed regardless of what was learned throughout the proceedings.  

The detailed statement will remain a requirement, but the proceedings will be governed and delimited by pleadings, which can be amended in the ordinary course of an action.

Old: 20-Year Patent Exclusivity 

New: Patent Terms Extended to Compensate for Market Approval Delay

The patents at issue in the proceedings remained in force for a maximum of 20 years from the date of filing.  

Certificates of Supplementary Protection grant patent-like protection to compensate for some of the market exclusivity lost while the First Person awaited regulatory approval for its product. These certificates may be asserted in actions under the new regulations.

Old: Minister of Health a Party to the Proceedings


New: Minister of Health Kept Informed

The Minister of Health was a party to the proceeding but rarely participated. At the end of the proceeding, the Minister of Health was either prohibited from approving the product by an order of prohibition—or not.   The Minister of Health will receive regular updates on the proceeding to ensure timely issuance of generic or biosimilar approval. If the court issues a declaration of infringement, the Minister will be prohibited from approving the biosimilar or generic product until patent expiry.
Old: Certain Claims of Listed Patents Eligible for Litigation  

New: All Claims of Listed Patents Eligible for Litigation

Only certain eligible claims within a patent that appeared on the Patent Register were the subject of proceedings. 


The First Person will now be able to sue on all claims within patents that appear on the Patent Register. This means that in certain cases process claims, which have never before been part of these proceedings, will be the subject of litigation. 

Old: Patent Delisting Dispositive

  New: Patent Delisting Not Dispositive

A generic or biosimilar could challenge the eligibility for patent listing and, if successful, could have the proceeding against it summarily dismissed.

  A generic or biosimilar will be able to challenge the eligibility of a patent listing, but this will not dispose of the action.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Dominique T. Hussey
L.E. Trent Horne
Similar Articles
Relevancy Powered by MondaqAI
Osler, Hoskin & Harcourt LLP
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Osler, Hoskin & Harcourt LLP
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions